Fig. 3.

Incidence rates per 1000 PY for A infection, B malignancy, and C MACE/VTE outcome events of interest in patients with AT/AU and non-AT/AU AA. ^aThe total number of patients at risk (i.e., denominator) differed depending on whether the outcome event was chronic or acute. Therefore, the denominator was not always 599 for the AT/AU subtype or 8185 for the non-AT/AU subtype cohort. ^bExcluding nonmelanoma skin cancer. AT alopecia totalis, ATE arterial thromboembolism, AU alopecia universalis, BCC basal cell carcinoma, CABG coronary artery bypass graft, DVT deep vein thrombosis, IR incidence rate, MACE major adverse cardiovascular event, MI myocardial infarction, PCI percutaneous coronary intervention, PE pulmonary embolism, PY patient-years, SCC squamous cell carcinoma, VTE venous thromboembolic event